October 7, 2009 - CMS recently released to the Medicare Administrative Contractors (MACs), via transmittals 1817 and 106, reissued Guidance and Billing Instructions for the April 2009 changes to the National Coverage Determination (NCD) on Positron Emission Tomography (FDG).

Providers will have two new modifiers (in addition to the list of current modifiers) to consider when submitting claims with a date of service (DOS) on or after April 6, 2009 for CPT codes 78608, 78811-78816 for oncologic procedures.

Available on or after the implementation date of October 19, 2009, providers submitting claims with a DOS on or after April 6, 2009 for CPT codes 78608, 78811-78816 are now required to identify the procedure as either for initial treatment strategy or subsequent treatment strategy by appending the modifiers PI or PS, respectively.

CMS removed the previously identified ICD-9 range of codes allowing discretion at the local level with the Medicare Contractors. CMS did identify the combination of PI and ICD-9 codes that are newly non-covered 185 for adenocarcinoma of prostate.

Providers participating in the national oncologic PET registry (NOPR) for those procedures which continue to be covered only under coverage with evidence development (CED) continue to use the Q0 (zero) modifier and/or V70.7 in the second diagnosis position with condition code 30 in addition to using one of the two new modifiers below.

New Modifiers for PET Effective for Dates of Services (DOS) on or after April 6, 2009 Implemented on or after October 19, 2009

PI – Positron Emission Tomography (PET) or PET/Computed Tomography (CT) to inform the initial treatment strategy of tumors that are biopsy proven or strongly suspected of being cancerous based on other diagnostic testing. Short descriptor: PET tumor init tx strat

PS – Positron Emission Tomography (PET) or PET/Computed Tomography (CT) to inform the subsequent treatment strategy of cancerous tumors when the beneficiary's treating physician determines that the PET study is needed to inform subsequent anti-tumor strategy. Short descriptor: PET tumor subsq tx strategy

MACs have until October 19, 2009 to implement these changes in their systems. PET facilities will likely have similar transition time. Continue to submit your claims in accordance with past instructions until your local contractor issues local instructions and implementation date.

For more information: cms.hhs.gov


Related Content

News | Cardiac Imaging

April 23, 2024 — CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch ...

Time April 23, 2024
arrow
News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
arrow
News | Artificial Intelligence

January 23, 2024 — Quibim announced it has added an industry-leading cancer detection capability to its prostate tool ...

Time January 22, 2024
arrow
Feature | PET-CT | By Melinda Taschetta-Millane

According to research conducted by Polaris Market Research, the global positron emission tomography (PET)/computed ...

Time January 17, 2024
arrow
News | Prostate Cancer

January 5, 2024 — Perspective Therapeutics, Inc., announced that it has entered into a patent license agreement with ...

Time January 05, 2024
arrow
News | Radiology Business

December 27, 2023 — The American Roentgen Ray Society (ARRS) announced David M. Naeger, MD, as the 2024 ARRS ...

Time December 27, 2023
arrow
News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
News | RSNA

December 1, 2023 — In today's healthcare environment, the industry faces various pressing challenges. The magnetic ...

Time December 01, 2023
arrow
News | Radiology Imaging

November 30, 2023 — Through its leading imaging solutions and commitment to innovation, GE HealthCare remains at the ...

Time November 30, 2023
arrow
Subscribe Now